Italia markets close in 3 hours 51 minutes

PCAS SA (0NF7.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
8,05+8,05 (-29,64%)
Al 05:27PM BST. Mercato aperto.
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    PCAS: RESULTS AS OF JUNE 30, 2023

    + Ecully, September 6, 2023 RESULTS AS OF JUNE 30, 2023 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated results as of June 30, 2023, approved by today’s Board of Directors. 30 June 2022 30 June 2023 in millions of euros Net sales 109.8 113.4 EBITDA (*) -0.5 4.7 EBITDA margin -0.5% 4.2% Current operating income (*) -15.3 -11.0 Parmaceutical Synthesis -18.7 -18.3

  • GlobeNewswire

    Pcas: Net sales as of June 30, 2023

    Ecully, July 27, 2023 NET SALES AS OF JUNE 30, 2023 PCAS (Euronext Paris: PCA), a specialist in developing and producing complex molecules for life sciences and innovative technologies, has announced the publication of its consolidated net sales as of June 30, 2023. The PCAS Group has generated consolidated net sales of €113.4 million as of June 30, 2023, a 3.3% increase compared to the same period during the previous financial year (+2.9% at constant exchange rates). In millions of euros 2023 2

  • GlobeNewswire

    PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation

    Ecully, May 25th, 2023 PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation PCAS (Euronext Paris: PCA), specialized in the development of processes and production of complex molecules for Life Sciences and Specialty Chemicals Markets, has made the decision to sell PCAS Canada Inc., the Canadian subsidiary of PCAS Group, to DIC Corporation, a Japanese chemicals group with a presence in more than 60 countries. An enterprise value of 88.2 million euros has been agreed for PCAS